Unaware of Any Undisclosed Material Change
October 15, 2021 10:42 ET
|
Arch Biopartners
TORONTO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- At the request of the Investment Industry Regulatory Organization of Canada (IIROC), Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and...
Arch Biopartners Provides Update on Phase II Trial for LSALT Peptide
August 05, 2021 06:30 ET
|
Arch Biopartners
TORONTO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Arch Scientists Awarded CIHR Grant to Study LSALT for the Prevention of Chronic Disease
July 14, 2021 07:00 ET
|
Arch Biopartners
TORONTO, July 14, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation
June 10, 2021 07:20 ET
|
Arch Biopartners
TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Arch Biopartners Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19
May 04, 2021 07:00 ET
|
Arch Biopartners
TORONTO, May 04, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin for the Treatment and Prevention of Acute Kidney Injury
April 15, 2021 07:00 ET
|
Arch Biopartners
Arch Biopartners is a clinical stage company developing new drug candidates for treating organ damage caused by inflammationNovel Mechanism of Action - selective dipeptidase-1 (DPEP-1) antagonists...
Turkish Ministry of Health Approves Increase in Patient Recruitment into the Phase II Trial for LSALT Peptide
March 30, 2021 07:57 ET
|
Arch Biopartners
TORONTO, March 30, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval from the Turkish Ministry...
Arch Biopartners Enters Exclusive License Agreement with the University of Cincinnati for AB569 Topical Wound Treatment
March 24, 2021 08:25 ET
|
Arch Biopartners
TORONTO, March 24, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has entered into an exclusive agreement with the...
Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide
March 16, 2021 08:33 ET
|
Arch Biopartners
TORONTO, March 16, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for...
ARCH Scientist Publishes Paper Showing Pre-Clinical Efficacy of AB569 in Eradicating Multi-Drug Resistant Pathogens Acinetobacter baumannii and Acinetobacter spp
March 04, 2021 08:32 ET
|
Arch Biopartners
TORONTO, March 04, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that one of its lead scientists, Dr. Daniel Hassett,...